Gh    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
3Spinal muscular atrophy1

3. Spinal muscular atrophy    [ 179 clinical trials,   102 drugs,   (DrugBank: 26 drugs),   52 drug target genes,   78 drug target pathways]
Searched query = "Spinal muscular atrophy", "Myelopathic muscular atrophy", "SMA I", "Werdnig-Hoffman disease", "SMA II", "Dubowitz disease", "SMA III", "Kugelberg-Welander disease", "SMA IV"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 179 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-002822-78-DE
(EUCTR)
09/01/200621/11/2005Can treatment with human growth hormone increase strength in spinal muscular atrophy type II and III? - SMA-GHCan treatment with human growth hormone increase strength in spinal muscular atrophy type II and III? - SMA-GH Spinal muscular atrophy (SMA) is an autosomal recessive disease. Due to the genetic defect, a molecule called spinal motor neuron” (SMN) protein is lacking, resulting in muscle weakness. In SMAs muscle weakness is found most often at the level of proximal muscles. The disease is life-threatening and chronically debilitating.Trade Name: Norditropin SimpleXx
Product Name: Norditropin SimpleXx 15 mg/1.5 ml
Product Code: GH
INN or Proposed INN: Somatropin
Other descriptive name: Norditropin SimpleXx
Klinik Neuropädiatrie und MuskelkrankheitenNULLNot RecruitingFemale: yes
Male: yes
20Germany